期刊文献+

某院住院患者利奈唑胺超说明书用药分析 被引量:3

Analysis of Off-Label Use of Linezolid Among Inpatients in a Hospital
下载PDF
导出
摘要 目的了解医院住院患者利奈唑胺超说明书用药情况,为临床合理用药和进一步的超说明书研究提供依据。方法统计广州市胸科医院2015年至2016年使用利奈唑胺住院患者的用药情况,按药品说明书判断其超说明书用药情况。结果共分析196条医嘱信息,其中超说明书用药占84. 18%,利奈唑胺超说明书用药共涉及超适应证(56. 90%)、超用法(25. 86%)、超用量(1. 38%)、超疗程(15. 86%),超说明书用药人数前3的科室为儿科、内一科、内四科。结论利奈唑胺超说明书用药情况较常见,均有指征和证据支持,但超用法用量和疗程尚无统一意见,需进一步形成高质量循证医学证据。 Objective To analyze the situation of off-label use of linezolid in our hospital, so as to provide reference for rational drug use and developing off-label drug use policy. Methods The drug use of linezolid for inpatients in Guangzhou Chest Hospital from 2015 to 2016 was analyzed. The situation of off-label drug use was analyzed according to drug label. Results A total of 196 doctors' orders were collected and analyzed to discover the occurrence of off- label use was 84.18%. The types of off- label drug use included off - indication(56.90% ), off - usage(25.86% ), off - dosage(1.38% ) and off - course(15.86% ). The top 3 departments of off - label use of linazolid were Department of Paediatrics, The First Department of Medicine and The Fourth Department of Medicine. Conclusion Off-label use of linezolid is common in our hospital, which is supported by indications and evidence. However, there is no consensus on the off-usage, off-dosage and off-course, and high- quality evidence based on medical evidence needs to be further developed.
作者 李卫 江慧贤 黄华英 钟洪兰 李祥 Li Wei;Jiang Huixian;Huang Huaying;Zhong Honglan;Li Xiang(Guanghzou Chest Hospital,Guangzhou,Guangdong,China 510095;Guangdong Food and Drug Vocational-Technical School,Guangzhou,Guangdong,China 510663)
出处 《中国药业》 CAS 2018年第23期93-95,共3页 China Pharmaceuticals
关键词 利奈唑胺 超说明书 循证学证据 合理用药 linezolid off - label use medical evidence rational drug use
  • 相关文献

参考文献7

二级参考文献61

  • 1肖成志.MDR-TB的化疗和化疗实施[J].临床药物治疗杂志,2005,3(2):27-31. 被引量:3
  • 2唐神结,肖和平,朱友生,尹洪云.抗分枝杆菌药物研究最新进展[J].国际呼吸杂志,2007,27(5):350-354. 被引量:3
  • 3梁莉,张滢蓉,乐军,景玲杰,高荣梁,肖和平.上海市非结核分枝杆菌感染趋势及耐药分析[J].中华医院感染学杂志,2007,17(7):895-897. 被引量:40
  • 4Madariaga MG,Lalloo UG,Swindells S.Extensively drug-resistant tuberculosis.Am J Med,2008,121(10):835-844.
  • 5Centers for Disease Control and Prevention (CDC).Extensively drug-resistant tuberculosis-United States,1993-2006.MMWR Morb Mortal Wkly Rep,2007,56(11):250-253.
  • 6World Health Organization.Guidelines for the programmatic management of drug-resistant tuberculosis:emergency update 2008.Geneva:World Health Organization,2008(WHO/HTM/TB/2008.402).
  • 7Prammananan T,Chaiprasert A,Leechawengwongs M.In vitro activity of linezolid against multidrug-resistant tuberculosis(MDR-TB) and extensively drug-resistant (XDR)-TB isolates.Int J Antimicrob Agents,2009,33(2):190-191.
  • 8Huang TS,Liu YC,Sy CL,et al.In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years.Antimicrob Agents Chemother,2008,52(6):2226-2227.
  • 9Tato M,de la Pedrosa EG,Cantón R,et al.In vitro activity of linezolid against Mycobacterium tuberculosis complex,including multidrug-resistant Mycobacterium bovis isolates.Int J Antimicrob Agents,2006,28(1):75-78.
  • 10Rodríguez JC,Cebrián L,López M,et al.Mutant prevention concentration:comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.J Antimicrob Chemother,2004,53(3):441-444.

共引文献251

同被引文献45

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部